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Background: Oseltamivir has been registered for use as post-exposition prophylaxis (PEP) following exposure to
influenza, based on studies among healthy adults. Effectiveness among frail elderly nursing home populations still
needs to be properly assessed.
Methods: We conducted a randomised double-blind placebo-controlled trial of PEP with either oseltamivir (75 mg
once daily) or placebo among nursing home units where influenza virus was detected; analysis was unblinded. The
primary outcome was laboratory-confirmed influenza among residents in units on PEP; the secondary outcome was
clinical diagnosis of influenza-like illness (ILI).
Results: 42 nursing homes were recruited, in which 17 outbreaks occurred from 2009 through 2013, two caused by
influenza virus B, the others caused by influenza virus A(H3N2). Randomisation was successful in 15 outbreaks, with
a few chance differences in baseline indicators. Six outbreaks were assigned to oseltamivir and nine to placebo.
Influenza virus positive secondary ILI cases were detected in 2/6 and 2/9 units respectively (ns); secondary ILI cases
occurred in 2/6 units on oseltamivir, and 5/9 units on placebo (ns). Logistical challenges in ensuring timely
administration were considerable.
Conclusion: We did not find statistical evidence that PEP with oseltamivir given to nursing home residents in
routine operational settings exposed to influenza reduced the risk of new influenza infections within a unit nor that
of developing ILI. Power however was limited due to far fewer outbreaks in nursing homes than expected since the
2009 pandemic. (RCT nr NL92738)
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Nursing home residents belong to the most vulnerable
groups as far as risk of serious influenza-related morbidity
and mortality is concerned. Therefore, nearly all nursing
home residents receive annual influenza vaccinations.
However, in this population the immune response to vac-
cination can be reduced related to age and co-morbidity,
and routine vaccination may not be sufficiently protective
for many vaccinated residents in relation to dose and* Correspondence: marianne.van.der.sande@rivm.nl
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article, unless otherwise stated.boosting, especially in those with low pre-vaccination ti-
ters [1-5]. A reduced immune response could also induce
serious, protracted illness, as well as slow recovery. Pre-
vention of influenza outbreaks in nursing homes could
therefore have major health gains for the residents as well
as reduce excess burden for nursing homes.
Oseltamivir can inhibit replication of influenza A and B
viruses, and may prevent further human-to-human trans-
mission [6]. Experimental [7] and observational [8] studies
among healthy adults and trials among healthy mainly
unvaccinated household contacts [9,10] showed high
effectiveness of prophylactic oseltamivir in prevention of
transmission, even when the index case was not treated
[10]. These observations cannot be extrapolated directlyCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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coverage might affect viral replication and excretion; a
high level of co-morbidity may affect relevant cellular and
immunological responses, multiple co-medication could
lead to drug interactions, and aging may modulate the
regular immune response. Nevertheless, observational
studies in nursing homes [11-14], also in the Netherlands
[15], have suggested that also here PEP with oseltamivir
could be effective in preventing transmission. So far, only
one randomised multi-centre study on the effectiveness of
oseltamivir prophylaxis among nursing home residents
has been published. Here, oseltamivir was prescribed
prophylactically for 6 weeks and not as PEP, but a 92% re-
duction in the incidence of laboratory confirmed influenza
compared with placebo was noted [16].
The uncertainty about the evidence-base for effective-
ness of PEP with oseltamivir in nursing homes is reflected
in the literature [17-24]. While acknowledging the absence
of sufficient data, both the Dutch Association of Nursing
Homes [25] and the Dutch National Centre for Infectious
Disease Control [26] recommended in 2004 implementa-
tion of PEP with oseltamivir in nursing home units with a
laboratory confirmed influenza patient, but also recom-
mended that if PEP was used, it should be scientifically
evaluated. A similar recommendation has been formulated
in the UK [27]. An evaluation in the Netherlands at the
end of the 2004–2005 season showed that although 65%
of nursing homes with a confirmed influenza outbreak
had implemented PEP at least to some degree, there was
no consensus on this policy. In particular the lack of evi-
dence for effectiveness in nursing homes was mentioned
(by 34%) as a major concern [28].
In view of the high risk among nursing home residents of
medical complications following an influenza infection, per-
sistent low uptake of influenza vaccination among nursing
home staf [29], insufficient evidence from RCTs in this
specific setting, and the potentially considerable budgetary,
ethical and logistical impact of the proposed intervention,
we conducted a double-blind placebo-controlled rando-
mised controlled trial to assess the effectiveness of PEP with




This was a double-blind, placebo-controlled randomised
controlled trial among Dutch nursing homes during four
influenza seasons in the period 2009–2013, coordinated
by the Centre for Infectious Disease Control (CIb) in the
Dutch National Institute for Public Health (RIVM). We
assumed that following a virological diagnosis of influenza,
without oseltamivir further transmission would occur in
40% of units, and we assumed that PEP with oseltamivir
will result in a reduction of at least 70% in units with newsymptomatic influenza-confirmed cases [9]. Then, we cal-
culated we would need to randomise 60 units to demon-
strate such a reduction with at least 80% power at the 5%
significance level. Assuming 30% of nursing homes experi-
ence an influenza outbreak, on average in 2 units, we
planned the study to run over three seasons. Due to the
expected unexpected pandemic, resulting in much lower
attack rates among the elderly, and very few outbreaks in
nursing homes since, the study was extended to four
seasons.
Nursing homes were recruited throughout the coun-
try, with a view to obtaining a representative sample of
Dutch nursing homes. After written consent was ob-
tained from the nursing home, residents or if indicated
their legal representatives were provided with informa-
tion and requested for their written consent to partici-
pate in the trial, in case their unit would be hit by
influenza and be randomised to PEP with study medica-
tion. As turn-over of residents in nursing homes is con-
siderable, this procedure to inform and obtain consent
before any actual outbreak was updated every year in the
autumn, prior to the start of the influenza season. Fur-
thermore, when an actual outbreak occurred, all resi-
dents on the affected unit who had not previously
consented or declined to participate, were still requested
for their consent to participate. Within each unit with
an influenza outbreak, all consenting residents who were
not ill were eligible for PEP. Units were excluded if there
were less than five consenting residents; individual resi-
dents diagnosed by their treating physicians to suffer
from chronic renal failure were not eligible [30,31].
In each participating nursing home, a contact person
was identified who was responsible for coordinating and
managing the study. All participating nursing homes
were visited to explain the study to staff and manage-
ment; staff were trained in identification of ILI and stan-
dardised collection of respiratory specimens and data.
ILI was clinically diagnosed by the treating physicians in
the nursing homes, and defined according to the ECDC
EU case definition as a sudden onset of symptoms and
at least one of the following four systemic symptoms:
fever or feverishness, malaise, headache, myalgia, and at
least one of the following three respiratory symptoms:
cough, sore throat, shortness of breath (http://ecdc.eur-
opa.eu/en/activities/surveillance/eisn/surveillance/pages/
influenza_case_definitions.aspx). An influenza outbreak
was defined as virological confirmation of influenza in a
respiratory specimen of one or more residents with ILI
from the same unit where ILI was diagnosed. For each
nursing home, the collaborating laboratory was identi-
fied and informed about the study by the study team.
In case of a suspected influenza outbreak in a nursing
home unit, a nasopharyngeal specimen was collected from
such an index patient for testing at the local laboratory
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chain reaction (PCR) assays according to local practices,
in line with the intention to perform the trial in as much a
real life situation as possible. Laboratories were requested
to send part of the specimen to the coordination Centre
for Infectious Disease Control (CIb) at the Dutch National
Institute for Public Health and the Environment (RIVM)
for further characterisation and determination of antiviral
susceptibility. Upon confirmation of an outbreak by detec-
tion of influenza virus in the index ILI patient, study
medication was dispatched immediately from a central
storage location. Prior to the trial, randomization was per-
formed by an independent statistician, not connected with
the study team. The randomization code was used at the
central storage facility to prepare blinded study medica-
tion in the randomised sequence. The first outbreak re-
ceived the first blinded package, the second outbreak the
second blinded package etc. Outside the central storage
facility, no one involved in the study (staff and residents in
nursing homes, laboratories, investigators, monitors) were
aware of which medication was used, until the end of the
study when the code was broken.
The unit of randomization was a nursing home unit.
Units in which a virological confirmed influenza patient
had been identified, were eligible for randomization and
randomly allocated to receive either oseltamivir 75 mg or
a placebo during 10 days following the diagnosis of the
index patient. Index patients received therapeutic oselta-
mivir 75 mg twice daily for 5 days as per routine practice.Assessed for eligibility (n=24)
Excluded  (n=5)
Less than 5 participants in an unit (n=1)
Lack of virological confirmation of 
influenza in the ILI index case (n=2)
48 hours having elapsed since the start 
of the outbreak (n=2)
Analysed  (n=6)
Excluded from analysis because PEP study 
medication was not delivered according to 
protocol (n=1)
Follow-up (n=7)
Allocated to intervention (n=7)
Received oseltamivir as PEP (n=7)
Follow-up (n=10)
Allocated to intervention (n=10)
Received placebo as PEP (n=10)
Analysed  (n=9)
Excluded from analysis because PEP study 








Figure 1 Flow diagram a) by outbreak; b) by participants.All consenting not affected residents in the same unit
were offered PEP once daily with the randomised study
medication within 48 hours of onset of symptoms in the
index patient. Non-consenting residents did not receive
any PEP. Units where more than 48 hours had lapsed
since start of illness of the index patient were excluded
(Figure 1a).
Following the start of PEP, daily monitoring of intake of
PEP and of the development of influenza continued for 10
days. Daily information on the intake of PEP, influenza-
like illness, pneumonia, additional drug use, admissions
and serious adverse events (including death) was collected
on a checklist for all consenting participants. Baseline data
were collected in a standardised way on demographic
characteristics. If influenza-like illness occurred, a nose
swab and throat swab were collected for influenza virus
detection and further characterisation of detected influ-
enza viruses at the RIVM/CIb. In addition, these partici-
pants with ILI were immediately removed from the trial
protocol and offered therapeutic oseltamivir. To assess
asymptomatic transmission of influenza virus, participants
were requested for a nose swab and throat swab for influ-
enza virus detection at the RIVM/CIb at the end of PEP at
day 10 irrespective of having symptoms or not. In view of
the already existing registration of oseltamivir in this
population for this indication, the advanced age and med-
ical condition of most residents, monitoring of adverse
events focused on previously reported adverse events (in
particular new gastro-enteritis and allergic dermatologicalAssessed for eligibility (n= 379)
Excluded  (n=239)
Declined to participate (n=239)
Analysed  (n=36/41)
-Excluded from analysis because PEP study 
medication was delivered not according to 
protocol (n=4)
- Excluded from analysis because ILI 
symptoms at the first day of the study (n=1)
Virological analysis of 3/3 secondary ILI and 
29/33 at end of PEP
Not lost to follow-up (n=41/43)
-Died (n=2)
Allocated to intervention (n=54)
Received oseltamivir as PEP (n=43)
-Index patient (n=11)
Not lost to follow-up (n=71/73)
-Discontinued PEP (n=1), day 4
Discharged (n=1), day 5
Allocated to intervention (n=86)
Received placebo as PEP (n=73)
-Did not receive placebo as PEP, because 
of an index case (n=13)
Analysed  (n=63/71)
-Excluded from analysis because PEP 
study medication was delivered not according 
to protocol (n=7)
-Excluded from analysis because ILI 
symptoms at the first day of the study (n=1)
Virological analysis of 8/9 secondary ILI and 







Figure 2 Map of participating 42 homes with outbreak in black.
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sions, deaths). Standard operating procedures were drafted
and agreed upon with the participating public health
offices, nursing homes and medical laboratories.
Ethics
Ethical permission was granted by the Utrecht University
Medical Ethical Committee. The trial has been registered
in the Dutch Trial Register, which is part of the Dutch
Cochrane Centre, and which is incorporated in the meta-
Register of Controlled Trials, and a unique ISRCTN num-
ber (NL27938.041.09) has been allocated. All participants
or their legal representative provided written informed
consent. The trial was monitored to ensure adherence to
Good Clinical Practice.
Virologic analyses
From all collected specimens received at the central
laboratory total nucleic acid was extracted using the
MagNA Pure LC or MagNA Pure 96 automated extractor
(Roche) and analysed for the presence of RNA of influenza
virus types A and B using one-step real-time reverse tran-
scription PCR (rt RT-PCR) on a LightCycler 480 (Roche).
Detected type A viruses were further subtyped by rt RT-
PCR to determine the heamagglutinin (H) and neuramin-
idase (N) subtype. Of the detected type B viruses the
lineage was determined using rt RT-PCR. All A(H3N2)
influenza virus positive specimens were subjected to neur-
aminidase amino-acid substitution rt RT-PCR to deter-
mine the presence of the substitutions E119V and R292K
which are the most common substitutions associated with
oseltamivir reduced susceptibility in A(H3N2) influenza
viruses. If the viral load was high enough (Ct values equal
to or less than 30 in the detection rt RT-PCR), the H and
N genes of type A and B viruses and the M gene of type A
viruses were sequenced directly from the clinical speci-
men. In addition, these specimens were subjected to virus
isolation on tertiary Monkey Kidney (tMK) and Madin
Darby Canine Kidney (MDCK) cells, and if successful, the
virus isolates were subjected to phenotypic oseltamivir
susceptibility testing using the fluorogenic neuraminidase
inhibition assay. Detailed protocols and primers and
probes information are available on request.
Outcome
The primary outcome was an influenza virus infection
among residents on PEP in a unit with an influenza index
case. This was defined as the detection of a new virological
confirmed influenza infection in a participant who had
developed ILI under study medication in the same unit as
the index patient, at least 24 hours after the start of PEP.
The secondary outcome was a clinical diagnosis of ILI in
participating residents. Unblinding occurred after all data
were entered in the database. Analysis was per protocol.The chi-square test was used to test for a treatment effect
by comparing the numbers of units with at least one posi-
tive outcome in the placebo and oseltamivir groups. The
t-test was also used to test for a treatment effect by
comparing the proportions of primary and secondary
outcomes per unit in the two groups. All analyses were
done in the statistical package R.
Results
Forty-two nursing homes were recruited into the trial (see
map, Figure 2). During the first two years, immediately
following the 2009 pandemic, no outbreaks were reported
from any of the participating homes. In 2011/2012, 12
influenza outbreaks were reported, of which 11 were
included. In 2012/2013, 10 outbreaks were reported, of
which six were included. This is far less than the estimated
60 outbreaks we had expected in 30 nursing homes over a
two-year period, based on pre-pandemic data [28]. This
may also have contributed to some chance baseline differ-
ences between the two groups, but as p-values were small
this is not likely. Reasons for non-inclusion of five out-
breaks were fewer than five consenting residents on a unit
(1x), lack of virological confirmation of influenza in the
ILI index case (2x) and/or more than 48 hours having
elapsed since the start of the outbreak (2x) (Figure 1a).
In total, 17 outbreaks of influenza in 8 of 42 (19%)
nursing homes were recruited into the trial. Fifteen of
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for 13/15 the subtype was determined from other ILI
cases during PEP as most diagnostic laboratories did not
subtype type A influenza viruses. Nearly all of these
outbreaks were caused by influenza virus A(H3N2). Two
outbreaks (both in the oseltamivir arm) were caused by in-
fluenza virus type B. All of the index cases were prescribed
therapeutic oseltamivir 75 mg BD for 5 days. In 15 of 17
(88%) outbreaks, in seven homes, PEP study medication
was delivered according to protocol, and 99 non-ill
residents were included and received PEP. For only one
participant, consent was not obtained prior to the start of
the influenza season. Of these 15 units, six (36 residents)
were allocated to oseltamivir and nine (63 residents) to
placebo (see Figure 1 a and b; flow diagrams by units and
by residents). Table 1 summarises baseline characteristics
of the study population. In the participating nursing home
units assigned to placebo, residents were overall slightly
younger and less often vaccinated (Table 1).
In six of seven units where secondary cases of ILI were
diagnosed, specimens from residents with ILI were col-
lected at the start of the ILI and submitted for influenza
virus detection; on the 7th unit only an end-of-therapy
specimen was available. Influenza virus positive second-
ary ILI cases were detected in 2/6 (33%) units on oselta-
mivir (1x influenza virus type B Yamagata lineage, 1x
influenza virus A(H3N2)) and in 2/9 (22%) units on
placebo (all influenza virus A(H3N2)), which was not a
statistically significant difference. Secondary cases of ILI
during PEP were diagnosed in 2/6 (33%) units on oselta-
mivir and in 5/9 (55%) units on placebo, which did not
provide statistical evidence of a treatment effect either.
Adjusting for size of the unit (taking the fraction of cases
as outcome) did not change the lack of statisticalTable 1 Characteristics of study population (n=99
participants)
Placebo (n = 63) Oseltamivir (n = 36)
Units 9 (60%) 6 (40%)
Units in first season N (%) 6 (67%) 3 (50%)
No. (%) females 39 (61.9%) 26 (72.2%)
Mean age (years) (SD) 79.1 (9.4) 83.7 (8.4)
- Female 81.6 (9.0) 85.9 (5.9)
- Male 75.0 (8.7) 78.0 (11.4)
No (%) vaccinated
- 2011/2012 32 (76.2%) 17 (100%)
- 2012/2013 19 (90.5%) 19 (100%)
Total (%) 51 (81.0%) 36 (100%)
Side effects (n participants) 2 5
Discontinued (n participants) 2 2significance of either of these estimates (p-values of 0.2
and 0.8 resp.). In 3/9 units on placebo secondary ILI
cases could not be confirmed as caused by influenza
virus infection, whereas in both units with secondary ILI
cases on oseltamivir this was confirmed to be an influ-
enza virus infection. At individual level, 2 (67%) partici-
pants with ILI in the oseltamivir group and 6 (67%; 8/9
tested) in the placebo group tested influenza positive. Of
all PEP participants tested, regardless of ILI, 3/32 (9%)
in the oseltamivir and 10/47 (21%) in the placebo group
tested positive.
A(H3N2) positive specimens from index cases (n = 11),
secondary ILI cases (n = 6) and specimens collected at
end-of-PEP (n = 4) were available for further virological
analysis from 1/6 units on oseltamivir and 7/9 units on
placebo. None of the sequenced A(H3N2) viruses from
the index patients, secondary ILI cases during oseltamivir
or placebo PEP, nor the end-of-PEP placebo specimens
showed evidence for NA-E119V or NA-R292K or other
amino acid substitutions associated with reduced suscepti-
bility for oseltamivir. Four A(H3N2) influenza viruses
were available for phenotypic antiviral susceptibility test-
ing; none of them showed reduced inhibition with oselta-
mivir. The neuraminidase sequences of one index case
and of two secondary ILI cases from this unit on placebo
PEP were identical and unique in a background of influ-
enza surveillance A(H3N2) viruses from the same time
period confirming ongoing transmission of A(H3N2) virus
on this unit.
Four participants discontinued the study, of which two
died (both in the oseltamivir group) which were consid-
ered to be due to advanced age, poor general health and
underlying co-morbidities. According to the nursing
home physician, these deaths were not related to partici-
pation in the trial or study medication. Two of the index
cases also passed away in spite of oseltamivir treatment.
Otherwise, reported side effects among trial participants
were mild and limited. Among 36 residents who took
oseltamivir as study medication only a side effect of diar-
rhoea was reported by two (5.6%) participants. Five of 63
residents on placebo reported side effects: diarrhoea
(1.6%), repeated nosebleed (1.6%), sore throat, hoarse-
ness and cough (1.6%) and muscle pain and coughing
(3.2%); none of the participating residents discontinued
due to side effects.
Discussion
We failed to find statistically significant evidence for a
protective effect of post-exposure prophylaxis with oselta-
mivir on influenza transmission among exposed nursing
home participants. While there was a lower proportion of
units where ILI occurred if oseltamivir rather than placebo
was used, laboratory-confirmed influenza virus transmis-
sion as measured among secondary ILI cases was found in
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to placebo. At individual level, an influenza virus infection
was detected in fewer residents receiving oseltamivir
prophylaxis then in residents who received placebo
prophylaxis. Although we had limited data, we also found
no evidence that use of oseltamivir as PEP induced
antiviral resistance.
The fact that the start of the RCT coincided with the
2009 pandemic was unexpected and the much lower inci-
dence of influenza among the elderly population post-
pandemic therefore resulted in an underpowered study:
only fifteen nursing home units could be included com-
pared to the desired sample size of 60. Pre-pandemic data
suggested that 30% of nursing homes would experience
influenza outbreaks each season, on average affecting two
units [28]. In our study, no outbreaks were reported in the
first two post-pandemic years, and in the additional two
years together only 20% of houses reported outbreaks, on
average still two units per house being affected. Further
extension in time was not possible as the study medication
provided would no longer be useable. Even if it had been
possible to obtain new study medication similar to the ori-
ginal batches, the low influenza incidence in the winter of
2013/2014 suggests that few additional outbreaks would
have been included, not alleviating the lack of power due
to attack rates much lower than pre-pandemic. The lower
infection rates among elderly populations for influenza
virus A(H1N1)pdm09, the 2009 pandemic virus, was
already clear shortly after the emergence of the 2009 pan-
demic [32,33]. Indeed, in none of the nursing home out-
breaks in this trial, influenza virus A(H1N1) or A(H1N1)
pdm09 was detected, even though these were the domin-
ant influenza strains circulating in the communities dur-
ing most of these years. Only in the 2011/2012 season,
significant circulation of influenza virus A(H3N2) was
observed in the Netherlands, coinciding with the year with
the largest number of outbreaks [34,35].
In spite of randomisation, some baseline differences
were observed among the two groups. Although ran-
domisation is designed to make units comparable with
regards to known and unknown confounders, by chance
some differences can occur. The lower age in the pla-
cebo group might have somewhat reduced the risk of
influenza virus transmission occurring in these groups,
while the lower vaccination uptake might have resulted
in a slightly increased risk. Thus, it is likely that this
imbalance between the groups had little overall effect on
the outcome of the trial. We did not present adjusted
outcomes, as adjustment would contradict the rationale
of a RCT, but in any case adjustment did not change the
outcomes (data not shown) [36]. Furthermore, in spite
of block randomisation by four, a logistical mix-up oc-
curred, resulting in a less optimal randomisation process
and unequal group sizes.Logistical challenges in ensuring that residents would
receive PEP within 48 hours of onset were considerable.
This did not relate so much to the set-up of the trial
(the delay of dispatching the study medication from the
central storage was on average less than 2 hours), as to
the delay in obtaining informed consent from individual
participants, in particular if this needed to be obtained
from relatives, as well as delays in the process to confirm
influenza virus infection in the index patient (relating to
within-house logistics of collecting a sample from a sus-
pected index case, getting the sample to the local labora-
tory, receiving the virology results, and notifying the
responsible professionals). As the effectiveness of oselta-
mivir is assumed to be strongly correlated with timely
administration, this will have reduced our chances of
finding an effect if there might have been one. However,
as we wanted to assess the real-life effectiveness, we de-
liberately opted for a real-life situation whereby nursing
homes would follow a routine protocol, which would be
sustainable outside the trial [37]. Although residents
who had not yet consented to participate prior to the
outbreak were again approached at the start of the out-
break, this did not result in improved uptake; in this
setting rapid decision making could not be ensured.
Randomisation should have ensured that deviation from
protocol with respect to swabbing, testing and use of the
intervention were random. Nevertheless, if start of PEP
was relatively late (albeit within 48 hours), this will have
resulted in a dilution of any real effect. Indeed, availabil-
ity of a rapid and reliable bed-side test might be an
essential prerequisite to enable timely start of PEP (and
therapeutic) oseltamivir in a nursing home setting; rapid
start of therapeutic oseltamivir can also limit ongoing
transmission.
In recent years, the effectiveness of therapeutic use of
oseltamivir has come under scrutiny. In particular, more
data have been demanded to assess effectiveness to
prevent complications in ill patients [38]. This debate
might also have an impact on actual use, as preliminary
data from a recent nationwide Dutch study in 34
nursing homes [39] suggested only a minority (less than
20%) of participants with ILI were prescribed thera-
peutic oseltamivir (J van der Steen/S Hendriks, personal
communication), compared to the 89% of nursing home
physicians reporting to prescribe therapeutic oseltamivir
for ILI in 2006 [28]. Also prophylactic use of oseltamivir
may need more research in real life situations. As many
mathematical models have assumed a significant impact
of antiviral use by exposed people on transmission, pol-
icy makers have invested in storage of antivirals in case
of a severe influenza outbreak. However, model assump-
tions need to be fed by data, and the need for more data
on the actual impact of prophylactic use of antivirals
has emerged in discussions on the (cost)effectiveness of
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2009 pandemic. Our study tried to fill part of this the
gap with regards to the need for evidence on the
effectiveness of oseltamivir as PEP during the annual
outbreaks in nursing homes.
Conclusions
In spite of an ambitious design, the lack of influenza out-
breaks among the elderly in the wake of the pandemic-
driven change in dominant circulating influenza strains,
has resulted in an underpowered study, which may have
contributed to our inability to demonstrate effectiveness
of oseltamivir as PEP to reduce the incidence of influenza
outbreaks in nursing homes. The debate on the effective-
ness of oseltamivir as PEP among nursing home residents
remains open therefore and the current recommendation
for Dutch nursing homes that if PEP is used, then scien-
tific evaluation of its effectiveness is indicated, still stands.
As long as the current low incidence of seasonal influenza
in elderly populations persists, it will be challenging to
achieve the power needed in a real life situation in a single
study to demonstrate effectiveness or lack of effectiveness
in a conclusive manner, and meta-analysis of single studies
might be needed. Well-designed trials such as this one
provide the much needed data to enable such integrated
assessments. At the same time, insight into trends in the
burden of disease of influenza remains essential, as the
logistical challenges needed to ensure timely implementa-
tion are considerable, and can only be justified if recurrent
outbreaks continue to cause significant morbidity and
mortality.
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